About us

RTW is a life sciences investment and innovation firm

Made up of scientists, entrepreneurs and investors; we forge new paths together, invest in each other and believe in each other.

77

team members at RTW

Jixing White Artiva White C4 White Dermtech White Encoded Therapeutics White Established Labs White Jixing White Stoke Therapeutics White Tarsus White

At the end of the day, we’re looking to identify companies that are going to make a major difference in patients’ lives and support them both financially and through our expertise. As a result, we hope to participate in the value creation that comes with their success.

Roderick Wong, MD Managing Partner, Chief Investment Officer

70

private companies invested in*

*as of July 2022

Great science takes place everywhere

RTW prioritizes advancing early stage scientific development as reflected in its global portfolio.

Location
USA

We have a core focus on the US, with deep coverage of opportunities from academia to mid-size public companies. We apply a full range of deal execution and company building capabilities. 

United Kingdom

We are committed to fostering the UK life sciences ecosystem, partnering with universities, in-licensing academic programs, and supporting UK entrepreneurs with capital and expertise. 

Netherlands & Belgium

Portfolio companies include argenx, uniQure, ProQR, and iTeos Therapeutics.

Germany, Spain, Switzerland & Nordic countries

Portfolio companies including Rocket Pharmaceuticals

Israel

Companies based here include UroGen Pharma, BrainsWay

China

Based in Shanghai, JiXing is a conduit to bring western innovation to the Chinese market through a trusted and established China-based company

Our approach

Identify unmet needs

We believe the best way to create value for investors is to find and support innovations that solve unmet needs for patients.

Invest in relationships

We believe in developing long-term relationships with great entrepreneurs and scientists who are as passionate about medicine as we are.

Support through the lifecycle

Our high-conviction approach means we are committed for the long term, allowing us to help drive value creation at each stage for investors, companies, and ultimately patients.

Our story

Doctors, academics, and drug developers. Seasoned venture capitalists and investment bankers. Experienced lawyers, data scientists, and company operators. We all work as one team. Applying our collective power to build successful companies around brilliant ideas.

Also in this section

Our vision, values and purpose

These things shape the what, why, and how of our firm. They're what drives our impact on our partners, companies, colleagues, patients, and the world around us.

Our strategy

Our strategy starts with science. Scientific research and idea generation are our foundation and the way we discover sources of transformational innovations. We build on that science with our financial investment, company building, transactional, and legal expertise to create impact.

Our business model

Science doesn't care about company stage, so neither do we. Full lifecycle investing means we can invest in and support the best science regardless of where it sits. From company creation to early stage venture to crossover and public company investing. Our structure and financial capabilities allow us the flexibilty to support our portfolio companies' needs through a broad range of financing models.

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.